期刊文献+

新活素前置应用对急性心肌梗死急诊PCI病人预后影响的临床研究 被引量:9

Clinical study on the influence of pre-application neoactivin on prognosis in emergency percutaneous coronary intervention patients with acute myocardial infarction
暂未订购
导出
摘要 目的:分析新活素前置应用对急性心肌梗死急诊经皮冠脉介入术(PCI)术后病人心功能、氨基末端脑利钠肽前体(NT-ProBNP)水平、心肌微循环及心脏不良事件发生的影响。方法:选取2020-2021年住院治疗的急性心肌梗死88例病人作为研究对象,随机分为观察组43例和对照组45例,所有病人入院后均行急诊PCI手术治疗,观察组病人确诊后在规范药物治疗的基础上立即启动新活素治疗,对照组不应用新活素治疗。比较2组病人的心功能、NT-ProBNP水平、心肌微循环以及不良事件发生情况。结果:观察组心功能优于对照组,其左心室射血分数高于对照组,左心室舒张末期容积、左心室舒张末期内径低于对照组(P<0.01);观察组NT-ProBNP水平低于对照组(P<0.01);观察组心肌梗死溶栓血流分级高于对照组(P<0.01)、计帧值低于对照组(P<0.01);观察组发生心肌梗死、恶性心律失常、心力衰竭、心源性猝死等不良事件发生率低于对照组(P<0.05)。结论:急性心肌梗死急诊PCI病人前置使用新活素进行治疗,可显著改善心功能,降低NT-ProBNP水平,改善心肌微循环,降低心脏不良事件的发生。 Objective:To analyze the effects of neoactivin pre-application on cardiac function,NT-ProBNP level,myocardial microcirculation and adverse cardiac events in patients with acute myocardial infarction after emergency percutaneous coronary intervention(PCI).Methods:A total of 88 patients hospitalized from 2020 to 2021 were selected as the study objects,and randomly divided into the observation group(43 cases)and the control group(45 cases).All patients were treated with emergency PCI.The patients in the observation group were immediately treated with neoactivin on the basis of standard drug treatment after diagnosis,while the control group was not treated with neoactivin.The cardiac function,the level of NT-ProBNP,myocardial microcirculation and the occurrence of adverse events were observed and compared between the two groups.Results:The heart function of the observation group patients was better than that of the control group,with a higher left ventricular ejection fraction,lower left ventricular end diastolic volume,and lower left ventricular end diastolic diameter compared to the control group(P<0.01).The level of NT-ProBNP in the observation group was lower than that in the control group(P<0.01).The thrombolytic blood flow grading of myocardial infarction in the observation group was higher than that in the control group(P<0.01),and the frame count value was lower than that in the control group(P<0.01).The incidence of adverse events such as myocardial infarction,malignant arrhythmia,heart failure and sudden cardiac death in the observation group was significantly lower than that in the control group(P<0.05).Conclusions:Pre-application of neoactivin in emergency PCI patients with acute myocardial infarction can significantly improve cardiac function,reduce the level of NT-ProBNP,improve myocardial microcirculation and reduce the occurrence of adverse cardiac events.
作者 吴纲 李雪冬 曹超 王真 邵胜胜 胡业梅 WU Gang;LI Xue-dong;CAO Chao;WANG Zhen;SHAO Sheng-sheng;HU Ye-mei(Department of Cardiovascular Medicine,Bengbu Second People′s Hospital,Bengbu Anhui 233000,China)
出处 《蚌埠医学院学报》 CAS 2023年第9期1211-1214,共4页 Journal of Bengbu Medical College
基金 安徽省蚌埠市科技创新指导类项目(20220109)。
关键词 心肌梗死 经皮冠状动脉介入术 心功能 新活素 myocardial infarction percutaneous coronary intervention cardiac function neoactivin
  • 相关文献

参考文献9

二级参考文献119

  • 1李世强,傅向华,刘君,谷新顺,张晶,樊欣娜,姜云发,苗青.静脉注射重组人脑利钠肽对急性心肌梗死伴心力衰竭患者的急性血流动力学效应的研究[J].中华心血管病杂志,2006,34(1):23-27. 被引量:102
  • 2Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates : ACC/AHA guidelines for the management of patients with ST- elevation myocardial infarction (updating the 2004 guideline and 2007 focused update ) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update ) a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines [ J ]. J Am Coil Cardiol, 2009, 54 ( 23 ) : 2205- 2241.
  • 3Silber S, Albertsson P, Avil6s FF, et al. Guidelines for percutaneous coronary interventions. The task force for peroutaneous coronary interventions of the European Society of Cardiology[J]. Eur Heart J, 2005, 26(8) :804-847.
  • 4Yellon DM, Hausenloy DJ. Myocardial reperfusion injury [ J ]. N Engl J Med, 2007, 357(11) :1121-1135.
  • 5Ovize M, Baxter GF, Di Lisa F, et al. Postconditioning and protection from reperfusion injury: where do we stand? Positionpaper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology[ J]. Cardiovasc Res, 2010, 87 ( 3 ) :406-423.
  • 6Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion : comparison with ischemic preconditioning [ J ]. Am J Physiol Heart Circ Physiol, 2003, 285 (2) : H579-H588.
  • 7Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart[ J]. Circulation, 2005, 112(14) :2143-2148.
  • 8Zhao ZQ, Vinten-Johansen J. Posteonditioning: reduction of reperfusion-induced injury [ J ]. Cardiovasc Res, 2006, 70 ( 2 ) : 200-211.
  • 9Thibauh H, Piot C, Staat P, et al. Long-term benefit of postconditioning[ J ]. Circulation, 2008, 117 ( 8 ) : 1037-1044.
  • 10LCnborg J, Kelbaek H, Vejlstrup N, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance[ J]. Circ Cardiovasc Interv, 2010, 3( 1 ) :34-41.

共引文献1192

同被引文献141

引证文献9

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部